Reason for request
The actual benefit of AXELER products is substantial.
Clinical Added Value
|no clinical added value||
AXELER 20 mg/5 mg, 40 mg/5 mg and 40 mg/10 mg fixed-dose combinations of olmesartan medoxomil 20 or 40 mg and amlodipine besilate 5 or 10 mg provide no improvement in actual benefit (IAB V) in comparison with concurrent use of the two active substances taken separately.